PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 130-133 C-reactive protein Homo sapiens 96-99 33745599-12 2021 CONCLUSIONS: The EPA and DHA levels were related to C-reactive protein (CRP) of inflammation maker, but non-significant associated with development allergic diseases. Eicosapentaenoic Acid 17-20 C-reactive protein Homo sapiens 52-70 33745599-12 2021 CONCLUSIONS: The EPA and DHA levels were related to C-reactive protein (CRP) of inflammation maker, but non-significant associated with development allergic diseases. Eicosapentaenoic Acid 17-20 C-reactive protein Homo sapiens 72-75 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 31-34 C-reactive protein Homo sapiens 62-80 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 31-34 C-reactive protein Homo sapiens 82-85 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 130-133 C-reactive protein Homo sapiens 96-99 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 157-160 C-reactive protein Homo sapiens 62-80 33418065-7 2021 With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (beta = -1.3121 (95% CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Eicosapentaenoic Acid 157-160 C-reactive protein Homo sapiens 82-85 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 130-133 C-reactive protein Homo sapiens 96-99 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 122-125 26137879-9 2015 Although compatible with no association, women in the highest tertile of erythrocyte eicosapentaenoic acid had a nonsignificant 32% (95% CI: -23 to 62%) reduced breast tissue CRP. Eicosapentaenoic Acid 85-106 C-reactive protein Homo sapiens 175-178 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 224-227 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 122-125 33418065-8 2021 Using only studies that supplied EPA and DHA in the range of 2 g to 6 g, the ratio of EPA to DHA was also associated with CRP (beta = -2.10429 and 95% CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Eicosapentaenoic Acid 86-89 C-reactive protein Homo sapiens 224-227 33418065-10 2021 CONCLUSION: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g to 6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. Eicosapentaenoic Acid 42-45 C-reactive protein Homo sapiens 96-99 33438442-11 2022 More beneficial effects of EPA in survival were observed in men, pancreatic body-tail and low C-reactive protein patients. Eicosapentaenoic Acid 27-30 C-reactive protein Homo sapiens 94-112 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Eicosapentaenoic Acid 5-8 C-reactive protein Homo sapiens 126-144 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Eicosapentaenoic Acid 5-8 C-reactive protein Homo sapiens 146-149 29993265-8 2019 Both EPA (-0.56 mg/L; 95%CI: -1.13, 0.00) and DHA (-0.5 mg/L; 95%CI: -1.0, -0.03) significantly reduced the concentrations of C-reactive protein (CRP), respectively, especially in subjects with dyslipidemia and higher baseline CRP concentrations. Eicosapentaenoic Acid 5-8 C-reactive protein Homo sapiens 227-230 29993265-10 2019 The present meta-analysis provides substantial evidence that EPA and DHA have independent (blood pressure) and shared (CRP concentration) effects on risk factors of chronic diseases, and high-quality RCTs with multi-center and large simple-size should be performed to confirm the present findings. Eicosapentaenoic Acid 61-64 C-reactive protein Homo sapiens 119-122 25519029-5 2014 In the hyperlipidemic patients, the EPA administration significantly increased plasma adiponectin levels (p<0.05), accompanied by a decrease in insulin resistance designated by the HOMA-IR (homeostasis model assessment of insulin resistance) score (p<0.05) and Hs-CRP (high sensitivity C-reactive protein) value (p<0.05). Eicosapentaenoic Acid 36-39 C-reactive protein Homo sapiens 292-310 23351824-6 2013 Baseline eicosapentaenoic acid (EPA) but not docosahexaenoic acid (DHA) was inversely related to C-reactive protein, pentraxin-3, adiponectin, natriuretic peptide, and troponin levels. Eicosapentaenoic Acid 32-35 C-reactive protein Homo sapiens 97-115 23361365-0 2013 Docosahexaenoic acid and eicosapentaenoic acid reduce C-reactive protein expression and STAT3 activation in IL-6-treated HepG2 cells. Eicosapentaenoic Acid 25-46 C-reactive protein Homo sapiens 54-72 23361365-4 2013 The aims of this study were to examine the effect of the n-3 PUFAs, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), on the modulation of IL-6-induced CRP expression and to explore its possible mechanisms. Eicosapentaenoic Acid 100-121 C-reactive protein Homo sapiens 163-166 23361365-5 2013 We demonstrated that DHA and EPA inhibited IL-6-induced CRP protein and mRNA expression, as well as reduced CRP promoter activity in HepG2 cells. Eicosapentaenoic Acid 29-32 C-reactive protein Homo sapiens 56-59 23361365-5 2013 We demonstrated that DHA and EPA inhibited IL-6-induced CRP protein and mRNA expression, as well as reduced CRP promoter activity in HepG2 cells. Eicosapentaenoic Acid 29-32 C-reactive protein Homo sapiens 108-111 23351824-6 2013 Baseline eicosapentaenoic acid (EPA) but not docosahexaenoic acid (DHA) was inversely related to C-reactive protein, pentraxin-3, adiponectin, natriuretic peptide, and troponin levels. Eicosapentaenoic Acid 9-30 C-reactive protein Homo sapiens 97-115 25305703-1 2014 OBJECTIVE: We examined whether early loading of eicosapentaenoic acid (EPA) reduces clinical adverse events by 1 month, accompanied by a decrease in C-reactive protein (CRP) values in patients with acute myocardial infarction (MI). Eicosapentaenoic Acid 48-69 C-reactive protein Homo sapiens 149-167 25305703-1 2014 OBJECTIVE: We examined whether early loading of eicosapentaenoic acid (EPA) reduces clinical adverse events by 1 month, accompanied by a decrease in C-reactive protein (CRP) values in patients with acute myocardial infarction (MI). Eicosapentaenoic Acid 48-69 C-reactive protein Homo sapiens 169-172 25305703-1 2014 OBJECTIVE: We examined whether early loading of eicosapentaenoic acid (EPA) reduces clinical adverse events by 1 month, accompanied by a decrease in C-reactive protein (CRP) values in patients with acute myocardial infarction (MI). Eicosapentaenoic Acid 71-74 C-reactive protein Homo sapiens 149-167 25305703-9 2014 Peak CRP values after PCI in the EPA group were significantly lower than those in the control group (median [interquartile range], 8.2 [5.6-10.2] mg/dl vs 9.7 [7.6-13.9] mg/dl, p<0.01). Eicosapentaenoic Acid 33-36 C-reactive protein Homo sapiens 5-8 25305703-11 2014 CONCLUSIONS: Early EPA treatment after PCI in the acute stage of MI reduces the incidence of ventricular arrhythmias, and lowers CRP values. Eicosapentaenoic Acid 19-22 C-reactive protein Homo sapiens 129-132 23361365-10 2013 Taken together, our results demonstrate that DHA and EPA are able to reduce IL-6-induced CRP expression in HepG2 cells via an inhibition of STAT3 activation. Eicosapentaenoic Acid 53-56 C-reactive protein Homo sapiens 89-92 19763135-6 2009 EPA treatment significantly reduced the levels of immunoreactive insulin, triglycerides, SAA-LDL, CRP, PWV and CAVI and increased the levels of adiponectin relative to the control group for 3 months (P<0.05). Eicosapentaenoic Acid 0-3 C-reactive protein Homo sapiens 98-101 23268079-0 2012 [A case report of advanced gastric cancer with increased C-reactive protein(CRP) and decreased albumin levels: chemotherapy with nutritional supportive care using eicosapentaenoic acid (EPA)-enriched enteral nutrition agent]. Eicosapentaenoic Acid 163-184 C-reactive protein Homo sapiens 57-80 23268079-7 2012 Accordingly, nutritional supportive care using EN agent enriched with EPA during chemotherapy might be an effective treatment for patients with gastric cancer who show increased CRP and decreased albumin levels. Eicosapentaenoic Acid 70-73 C-reactive protein Homo sapiens 178-181 21427737-7 2011 At high RBC EPA and RBC DHA, these predicted increases were 13.9+-8.1 mg/dl (23%) and 12.0+-12.3 mg/dl (18%), respectively, for triglycerides and 0.5+-0.5 mg/l (50%) and -0.5+-0.6 mg/l (-34%), respectively, for CRP. Eicosapentaenoic Acid 12-15 C-reactive protein Homo sapiens 211-214 19185299-4 2009 METHODS: Cross-sectional associations of C-reactive protein (CRP) and Interleukin-6 (Il-6) with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) were evaluated in multivariable linear regression models adjusted for demographics, cardiovascular risk factors, medication use, exercise capacity, body-mass index, and waist-to-hip ratio. Eicosapentaenoic Acid 127-148 C-reactive protein Homo sapiens 41-59 19461006-14 2009 CONCLUSIONS: The study demonstrates that consuming 960 mg/d of EPA and 600 mg/d of DHA can lower CRP. Eicosapentaenoic Acid 63-66 C-reactive protein Homo sapiens 97-100 17192349-0 2007 Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Eicosapentaenoic Acid 9-30 C-reactive protein Homo sapiens 91-109 19628101-7 2009 Mean serum CRP concentrations tended to decrease as the intake of eicosapentaenoic acid, docosahexaenoic acid, or their combination increased in men and women, although none of these relationships was statistically significant. Eicosapentaenoic Acid 66-87 C-reactive protein Homo sapiens 11-14 17545695-7 2007 A multiple regression analysis showed that, especially in the middle tertile of long-chain n-3 PUFAs (eicosapentaenoic acid and docosahexaenoic acid) intake, CRP was inversely related to the intake of oleic acid and linoleic acid in both sexes and to the intake of alpha-linolenic acid in women. Eicosapentaenoic Acid 102-123 C-reactive protein Homo sapiens 158-161 16332649-11 2005 Eicosapentaenoic acid in phospholipids (P = 0.06) and CEs (P < 0.05) and linolenic acid in CEs (P < 0.05) were inversely related to C-reactive protein. Eicosapentaenoic Acid 0-21 C-reactive protein Homo sapiens 138-156 16825699-7 2006 RESULTS: After adjustment for several predictors of inflammation, the odds ratio of high CRP (> or =1.0 mg/L) for increasing quartiles of total n-3 PUFA and eicosapentaenoic acid + docosahexaenoic acid were 1.0, 0.72, 0.57, and 0.44 (P for trend = 0.01) and 1.0, 0.91, 0.76, and 0.54 (P for trend = 0.03), respectively. Eicosapentaenoic Acid 160-181 C-reactive protein Homo sapiens 89-92 12716789-10 2003 Serum C-reactive protein was significantly associated with percent linoleic acid and eicosapentaenoic acid in nonsmoking men (P = 0.03 and P = 0.04, respectively) and with docosahexaenoic acid in nonsmoking women (r = -0.46, P < 0.0001). Eicosapentaenoic Acid 85-106 C-reactive protein Homo sapiens 6-24 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. Eicosapentaenoic Acid 74-95 C-reactive protein Homo sapiens 11-14 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. Eicosapentaenoic Acid 97-100 C-reactive protein Homo sapiens 11-14 15514264-6 2004 Changes in CRP and VCAM-1 were inversely associated with changes in serum eicosapentaenoic acid (EPA) (r = -0.496, P = 0.016; r = -0.418, P = 0.047), or EPA plus docosapentaenoic acid (r = -0.409, P = 0.053; r = -0.357, P = 0.091) after subjects consumed the ALA Diet. Eicosapentaenoic Acid 153-156 C-reactive protein Homo sapiens 11-14 12821543-3 2003 After adjustment for other predictors of inflammation, intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was inversely associated with plasma levels of sTNF-R1 and sTNF-R2 (P=0.03 and P<0.001, respectively) and somewhat less so for C-reactive protein (P=0.08). Eicosapentaenoic Acid 85-106 C-reactive protein Homo sapiens 274-292 12821543-3 2003 After adjustment for other predictors of inflammation, intake of the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) was inversely associated with plasma levels of sTNF-R1 and sTNF-R2 (P=0.03 and P<0.001, respectively) and somewhat less so for C-reactive protein (P=0.08). Eicosapentaenoic Acid 108-111 C-reactive protein Homo sapiens 274-292 35232215-7 2022 EPA+DPA-FFA reduced least squares geometric mean high-sensitivity C-reactive protein by 5.8%; EPA-EE increased high-sensitivity C-reactive protein by 8.5% (P=0.034). Eicosapentaenoic Acid 0-3 C-reactive protein Homo sapiens 66-84 9059324-5 1997 Oral supplementation with eicosapentaenoic acid, in patients with cancer cachexia, resulted in a significant reduction in the serum concentration of the acute-phase protein C-reactive protein (11.0 +/- 4.8 mg/l before eicosapentaenoic acid compared with 0.8 +/- 0.8 mg/l after 4 weeks of eicosapentaenoic acid, P < 0.05), but no significant reduction in the serum concentration of the hepatocyte-stimulating cytokine interleukin-6. Eicosapentaenoic Acid 26-47 C-reactive protein Homo sapiens 173-191 9059324-5 1997 Oral supplementation with eicosapentaenoic acid, in patients with cancer cachexia, resulted in a significant reduction in the serum concentration of the acute-phase protein C-reactive protein (11.0 +/- 4.8 mg/l before eicosapentaenoic acid compared with 0.8 +/- 0.8 mg/l after 4 weeks of eicosapentaenoic acid, P < 0.05), but no significant reduction in the serum concentration of the hepatocyte-stimulating cytokine interleukin-6. Eicosapentaenoic Acid 218-239 C-reactive protein Homo sapiens 173-191 9059324-5 1997 Oral supplementation with eicosapentaenoic acid, in patients with cancer cachexia, resulted in a significant reduction in the serum concentration of the acute-phase protein C-reactive protein (11.0 +/- 4.8 mg/l before eicosapentaenoic acid compared with 0.8 +/- 0.8 mg/l after 4 weeks of eicosapentaenoic acid, P < 0.05), but no significant reduction in the serum concentration of the hepatocyte-stimulating cytokine interleukin-6. Eicosapentaenoic Acid 218-239 C-reactive protein Homo sapiens 173-191 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 142-163 C-reactive protein Homo sapiens 485-503 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 142-163 C-reactive protein Homo sapiens 557-575 35232215-12 2022 EPA+DPA-FFA also reduced triglycerides and high-sensitivity C-reactive protein without increasing low-density lipoprotein cholesterol. Eicosapentaenoic Acid 0-3 C-reactive protein Homo sapiens 60-78